Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial

Article Pharmacology & Pharmacy

Effect of papaverine on developmental hyperserotonemia induced autism spectrum disorder related behavioural phenotypes by altering markers of neuronal function, inflammation, and oxidative stress in rats

Kanishk Luhach et al.

Summary: The study found that papaverine can improve behavioral deficits related to autism spectrum disorder in rats with hyperserotonemia, and has significant effects on neuronal function, brain inflammation, and brain oxidative stress.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Attenuation of neurobehavioural abnormalities by papaverine in prenatal valproic acid rat model of ASD

Kanishk Luhach et al.

Summary: This study investigated the effects of a PDE10A inhibitor, papaverine, on core phenotypes of ASD in a Pre-VPA model in rats. Papaverine administration improved social behavior, anxiety, locomotion, and nociception, while also impacting protein markers associated with neuronal function. The findings suggest that targeting PDE10A could be a potential strategy for further understanding ASD phenotypes.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders

Sebastien Delhaye et al.

Summary: Phosphodiesterases (PDEs) are enzymes that regulate the homeostasis of cAMP and cGMP, with potential therapeutic implications for neurodevelopmental disorders.

MOLECULAR PSYCHIATRY (2021)

Add to Collection

Article Behavioral Sciences

Vinpocetine amended prenatal valproic acid induced features of ASD possibly by altering markers of neuronal function, inflammation, and oxidative stress

Kanishk Luhach et al.

Summary: Vinpocetine, a PDE1 inhibitor, ameliorated ASD-associated symptoms in rats prenatally exposed to VPA, possibly by improving neuronal function, brain inflammation, and oxidative stress. This study suggests PDE1 as a potential new pharmacological target for ASD treatment.

AUTISM RESEARCH (2021)

Add to Collection

Article Neurosciences

Double-blind, randomized, placebo-controlled pilot study of the phosphodiesterase-3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder

Mahmoud S. Abdallah et al.

Summary: Cilostazol has shown safe and effective antidepressant effects in patients with MDD, significantly reducing depression symptom scores, improving early response rates, and modulating various neurotrophic and inflammatory biomarkers.

CNS NEUROSCIENCE & THERAPEUTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder

Kanishk Luhach et al.

Summary: The study showed that cilostazol could alleviate prenatal VPA exposure-related hyperlocomotion, social interaction deficits, repetitive behavior, and anxiety, while significantly increasing biochemical markers such as BDNF, pCREB, IL-10, and GSH in the assessed brain regions.

JOURNAL OF PHARMACY AND PHARMACOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Mitochondrial dysfunction: A hidden trigger of autism?

Vellingiri Balachandar et al.

Summary: Autism is a complex neurodevelopmental and neuropsychiatric disorder with deficits in cognitive functions often linked to environmental and genetic factors. Mitochondria play a crucial role in autism, but research on its dysfunction is currently limited.

GENES & DISEASES (2021)

Add to Collection

Article Pharmacology & Pharmacy